ScreenerHero

HINDVyome Holdings Inc. Common Stock

NAS · US · Healthcare · Biotechnology · vyometx.com
2.250USD-3.02%Mkt Cap: 15.79M $P/E: —

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechn…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap15.79M $
Enterprise Value9.40M $
Revenue (TTM)129.72K $
Gross Profit218.77K $
Net Income (TTM)-10.26M $
Revenue/Share0.0180 USD
Last Price2.250 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.23
EV/Revenue72.42
P/S123.36
P/B2.65
EPS (TTM)-1.61
EPS (Forward)—
52W Range
1.7504% of range12.87
52W High12.87 USD
52W Low1.750 USD
Profitability
Gross Margin68.43%
Oper. Margin-3200.02%
EBITDA Margin0.00%
Profit Margin-3209.75%
ROE-420.22%
ROA-157.95%
Growth
Revenue Growth-46.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.75M $
CapEx (TTM)—
FCF Margin2807.21%
FCF Yield23.06%
Net Debt-7.87M $
Net Debt/EBITDA1.87
Balance Sheet
Debt/Equity0.01
Current Ratio4.37
Quick Ratio4.31
Book Value/Sh0.8620 USD
Cash/Share1.124 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateAug 15, 2025
Analyst Consensus
Rating—
Target (Mean)11.50 USD
Upside (mean)+411.1%
Target Range8.000 USD – 15.00 USD
$8.000+411.1% to mean$15.00
# Analysts2
Ownership
Shares Out.7.02M
Float3.65M
Insiders52.88%
Institutions2.18%
Short Interest
Short Ratio2.0d
Short % Float0.61%
Short % Out.0.39%
Shares Short27.39K
Short (prev mo.)35.14K
Technical
SMA 502.175 (+3.4%)
SMA 2002.869 (-21.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)11.00K
Avg Vol (10d)10.89K
Technical Indicators
RSI (14)55.9
MACD0.0280
MACD Signal0.0104
MACD Hist.+0.0176
BB Upper2.340 USD
BB Middle2.147 USD
BB Lower1.954 USD
BB Width17.94%
ATR (14)0.1036 USD
Vol Ratio (20d)0.46x